SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 5 - Annual statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-24-010262
Filing Date
2024-02-02
Accepted
2024-02-02 20:05:14
Documents
1
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm245141-3_5seq1.html 5  
1 OWNERSHIP DOCUMENT tm245141-3_5seq1.xml 5 5643
  Complete submission text file 0001104659-24-010262.txt   7132
Mailing Address C/O KERYX BIOPHARMACEUTICALS, INC. 750 LEXINGTON AVENUE NEW YORK NY 10022
Business Address
Oliviero James F III (Reporting) CIK: 0001434718 (see all company filings)

Type: 5 | Act: 34 | File No.: 001-38128 | Film No.: 24593574

Mailing Address 95 SAWYER ROAD SUITE 110 WALTHAM MA 02453
Business Address 95 SAWYER ROAD SUITE 110 WALTHAM MA 02453 781-652-4500
Checkpoint Therapeutics, Inc. (Issuer) CIK: 0001651407 (see all company filings)

IRS No.: 472568632 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)